Abstract:Parkinson's disease is primarily caused by the loss of dopaminergic neurons in the substantia nigra compacta. Ferroptosis, a novel form of regulated cell death characterized by iron accumulation and lipid peroxidation, plays a vital role in the death of dopaminergic neurons. However, the molecular mechanisms underlying ferroptosis in dopaminergic neurons have not yet been completely elucidated. NADPH oxidase 4 is related to oxidative stress, however, whether it regulates dopaminergic neuronal ferroptosis remains unknown. The aim of this study was to determine whether NADPH oxidase 4 is involved in dopaminergic neuronal ferroptosis, and if so, by what mechanism. We found that the transcriptional regulator activating transcription factor 3 increased NADPH oxidase 4 expression in dopaminergic neurons and astrocytes in an 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-induced Parkinson's disease model. NADPH oxidase 4 inhibition improved the behavioral impairments observed in the Parkinson's disease model animals and reduced the death of dopaminergic neurons. Moreover, NADPH oxidase 4 inhibition reduced lipid peroxidation and iron accumulation in the substantia nigra of the Parkinson's disease model animals. Mechanistically, we found that NADPH oxidase 4 interacted with activated protein kinase C α to prevent ferroptosis of dopaminergic neurons. Furthermore, by lowering the astrocytic lipocalin-2 expression, NADPH oxidase 4 inhibition reduced 1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine-induced neuroinflammation. These findings demonstrate that NADPH oxidase 4 promotes ferroptosis of dopaminergic neurons and neuroinflammation, which contribute to dopaminergic neuron death, suggesting that NADPH oxidase 4 is a possible therapeutic target for Parkinson's disease.

Crosstalk between regulatory non-coding RNAs and oxidative stress in Parkinson's disease

Emerging Clues of Regulatory Roles of Circular RNAs Through Modulating Oxidative Stress: Focus on Neurological and Vascular Diseases.

Circular RNAs: Novel Players in the Oxidative Stress-Mediated Pathologies, Biomarkers, and Therapeutic Targets

NFE2L2 variations reduce antioxidant response in patients with Parkinson disease.

The Role of Exosomal microRNAs and Oxidative Stress in Neurodegenerative Diseases

Pharmacological Modulation of Nrf2/HO-1 Signaling Pathway as a Therapeutic Target of Parkinson’s Disease

Oxidative Modification and Its Implications for the Neurodegeneration of Parkinson's Disease

Oxidative Stress-Induced Signaling Pathways Implicated in the Pathogenesis of Parkinson’s Disease

Pathophysiology of Ischemic Stroke: Noncoding RNA Role in Oxidative Stress

Nrf2 as a potential target for Parkinson’s disease therapy

The crosstalk between non-coding RNAs and oxidative stress in cancer progression

Long Noncoding RNAs in the Regulation of Oxidative Stress

The Crosstalk Between Oxidative Stress and DNA Damage Induces Neural Stem Cell Senescence by HO-1/PARP1 Non-Canonical Pathway

Oxidative stress in the aging substantia nigra and the etiology of Parkinson's disease

NOX4 Exacerbates Parkinson’s Disease Pathology by Promoting Neuronal Ferroptosis and Neuroinflammation

Single-Cell Sequencing Insights into the Transcriptional Landscape of Parkinson's Disease

Oxidative Stress in Neurodegenerative Diseases: From Molecular Mechanisms to Clinical Applications

Oxidative stress and regulated cell death in Parkinson’s disease

The mechanistic view of non-coding RNAs as a regulator of inflammatory pathogenesis of Parkinson's Disease

NRF2 Activation and Downstream Effects: Focus on Parkinson’s Disease and Brain Angiotensin

The crosstalk between reactive oxygen species and noncoding RNAs: from cancer code to drug role